Copenhagen, 2013-07-22 10:11 CEST (GLOBE NEWSWIRE) -- Company announcement
no. 18/2013
Pursuant to section 29 of the Danish Securities Trading Act, Zealand Pharma A/S (NASDAQ OMX: ZEAL.CO), hereby makes public, that the company has been informed that Idinvest Partners, 117 avenue des Champs-Élysées, 75008 Paris, France, now holds less than 5% of the share capital and the voting rights in Zealand Pharma A/S.
Following the sale of Zealand Pharma A/S shares Idinvest Partners now hold 1,079,397 shares, corresponding to 4.65 % of the share capital and voting rights in Zealand Pharma A/S.
# # #
For further information, please contact:
David Horn Solomon, President and Chief Executive Officer
Tel: +45 2220 6300
Hanne Leth Hillman, Vice President for IR & Corporate Communication
Tel: +45 5060 3689
About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of cardio-metabolic diseases, including diabetes and obesity, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved and launched (March 2013) in Europe under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA submission accepted in Feb 2013) and Japan (NDA filed in June 2012).
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com.
